ProSomnus® Sleep Technologies shared technology outcomes and discussed scientific data and clinical evidence shaping the future of OSA care at the ERS2026 in Barcelona.

ProSomnus® is the pioneer and global leader in Smart Sleep Medicine™, delivering precision, non-CPAP Oral Appliance Therapy (OAT) for Obstructive Sleep Apnea (OSA), with integrated multi-night physiologic monitoring enabled by its RPMO2 platform. A serious medical disease affecting over 1 billion people worldwide, OSA is linked to life-threatening comorbidities including heart failure, stroke, and type 2 diabetes. By integrating precision-engineered intraoral medical devices with advanced Remote Patient Monitoring (RPM) and data-driven diagnostics, ProSomnus is redefining the standard of care. Our platform is designed to provide continuous, nightly clinical insights that ensure superior adherence and validated patient outcomes. Non-invasive and patient-preferred, ProSomnus devices have demonstrated exceptional efficacy and safety across a rigorous and growing body of clinical evidence. ProSomnus precision devices are FDA-cleared, patented, and covered by commercial medical insurance, Medicare, and TRICARE, representing over 200 million covered lives globally. To learn more or find a provider near you, visit www.ProSomnus.com.